Developers of 16 Tech—a consortium of offices, laboratories, housing and retail space—believe the campus will become a powerful economic engine by fostering collaboration and innovation.
The decades-old system has long been criticized by experts for failing to catch problems with risky implants and medical instruments.
The escalation in per-share price—which far exceeds that of other recent deals involving Indiana public companies—reflects the unique nature of M&A in the pharmaceutical realm.
Justin Markel and Quinton Lasko are obsessed with feet and legs, technology and helping people improve their mobility. The combination led the duo to an invention designed to help athletes, although it has applications far beyond sports.
MiraVista Diagnostics, which processes more than 100,000 fungal-infection tests annually, plans to double the size of its headquarters near Indianapolis International Airport.
A few influential “serial entrepreneurs” in Indiana universities feel an itch to turn their discoveries into products and companies, over and over again.
The West Lafayette biotech firm’s stock traded as low as $1.41 last fall, following multiple setbacks and restructurings. But the stock had soared to $24 Thursday morning after news that it would be acquired by Novartis.
The deal represents a huge breakthrough for tiny Endocyte, which has about 90 employees in Indiana but has not yet launched a single product.
The Indiana Seed Fund III is an early-stage fund focused on developing startups in life sciences, health IT and agricultural biosciences.
The Eli Lilly and Co.-owned animal medicine maker’s shares rose to $36 each at closing Thursday, up from their $24 offering price.
The Corteva Agriscience spinoff, which includes the local operations of the former Dow AgroSciences unit, employs about 1,500 workers in Indianapolis.
The “Roche Academy” will provide mentors, internships and special curriculum to biology and chemistry undergrads, along with financial incentives and a job offer after graduation.
A federal appeals court ruled Thursday that the Trump administration endangered public health by keeping widely used pesticide chlorpyrifos, sold by Dow AgroSciences, on the market.
The Indianapolis-based pharmaceutical company said the division’s headquarters would remain in Greenfield after the spinoff and that no job cuts are planned.
U.S. Health and Human Services Secretary Alex Azar told lawmakers that it may be time to eliminate the complex system of rebates that drug companies and pharmacy-benefit managers use to negotiate and set prices.
The seventh recipient of the prize has been credited with protecting hundreds of species and millions of acres of critical habitat around the world. He will receive $250,000.
Alex Azar, secretary of Health and Human Services and a former executive of Eli Lilly and Co., said Monday that the Trump administration plans to turn up the heat on uncooperative pharma firms.
The Indianapolis-based pharmaceutical giant said it plans to acquire ARMO BioSciences Inc., which is working on treatments that activate the immune system of cancer patients to recognize and eradicate tumors.
The work-play-live district for innovation and entrepreneurship being developed on the near-northwest side will include research labs, apartments and bicycle trails—which could help to attract young workers.
DowDuPont Inc. is working on a series of deals to tighten the focus at two of the three spinoffs it plans for next year, including the Corteva Agriscience spinoff, which includes the Indianapolis operations of the former Dow AgroSciences unit.
